Inhatarget Therapeutics
Board
7 directors, 1 auditor, no change since 2025Chair of the board, permanent representative
appointed by deed of 29-09-2025
listed in the 2025 annual accounts, filed on 24-06-2026
Director, permanent representative
since 28-08-2019
term without a fixed end
listed in the 2025 annual accounts, filed on 24-06-2026
Director, permanent representative
since 04-12-2019
term without a fixed end
listed in the 2025 annual accounts, filed on 24-06-2026
Director
since 31-01-2020
term without a fixed end
listed in the 2025 annual accounts, filed on 24-06-2026
Director, permanent representative
since 31-01-2020
term without a fixed end
listed in the 2025 annual accounts, filed on 24-06-2026
Director
since 31-01-2020
term without a fixed end
listed in the 2025 annual accounts, filed on 24-06-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “7. Nomination d’administrateurs L’assemblée appelle aux fonctions d’administrateurs, pour une durée illimitée : Administrateur Représentant…”deed of 18-12-2019
Permanent representatives 4
Mandates through the years
12 names, the dashed line is todayChair of the board
Director
Director
Director
Director
Director
Director
Statutory auditor
Director
Director
Director
Director
LeadershipBoardEarlierend not dated
Mandates as a list
-
- Chair of the board, from 28-08-2019 to date
-
- Director, from 28-08-2019 to date
-
- Director, from 04-12-2019 to date
-
- Director, from 31-01-2020 to date
-
- Director, from 31-01-2020 to date
-
- Director, from 31-01-2020 to date
-
- Director, from 18-08-2020 to date
-
- Statutory auditor, from 09-06-2022 to date
-
- Director, appointed by deed of 02-09-2019, until 03-06-2020
-
- Director, appointed by deed of 02-09-2019, until 03-06-2020
-
- Director, appointed by deed of 18-12-2019, until 31-01-2020
-
- Director, from 28-08-2019, no longer listed in the 2025 annual accounts
Control
Shareholder
Equity €11.1m
Loss €3.7m in 2025 (loss €2.4m in 2024)
Checked score
34.27%
This company
Inhatarget Therapeutics
Equity €1.6m
Loss €921,288 in 2025
Capital
- Contribution
- €2,085,845.65
- Shares
- 105,502 in the deed of 03-06-2020
- Source
- deed of 23-01-2026
Owners through the years
as the annual accounts name themOwners as a list
-
- 2019: 42.76%
- 2020 to 2021: 41.97%
- 2022: 32.06%
- 2023 to 2024: 31.55%
- 2025: 34.27%
-
- 2021 to 2022: 10.14%
- 2023 to 2025: 15.2%
-
- 2020: 11.88%
Source: lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 02-09-2019 (in French)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Thursday of June at 15:00deed of 06-03-2023 (in French)
Shareholders
4 ownersOwners 4
- Equity €11.1m Loss of €3.7m in 2025 (loss of €2.4m in 2024) Checked score34.27%
- Equity €1.8m Loss of €8,247 in 2025 (loss of €11,275 in 2024) Checked score15.2%
- Equity €19.6m Profit of €2.5m in 2025 (profit of €3.8m in 2024) Checked scoreshare not stated
-
share not stated
Capital transactions
Shareholders according to the deeds
Stated in the deed
deed of 06-03-2023 ↗
- 7,995 shares
- 19 shares
- 68 shares
- 11,593 shares
- 8,300 shares
- 8,300 shares
- 4,397 shares
- 307 shares
- 184 shares
Stated in the deed
deed of 15-07-2022 ↗
- 7,995 shares
- 19 shares
- 68 shares
- 11,593 shares
- 8,300 shares
- 8,300 shares
- 4,397 shares
- 307 shares
- 184 shares
At incorporation
deed of 02-09-2019 ↗
- 3,998 shares (6.5%)
- 3,075 shares (5%)
- 3,075 shares (5%)
- 2,152 shares (3.5%)
- 49,200 shares (80%)
Capital over time
- 23-01-2026 Capital reduction of €1,755,316.52 · to €2,085,845.65 · to absorb losses
- 08-01-2026 Capital increase of €300,240.90 · 3,693 new shares at €81.30 per share · in cash
- 08-01-2026 Capital increase of €300,240.90 · 3,693 new shares · in cash
- 16-01-2024 Capital reduction of €3,151,684 · to absorb losses
- 24-07-2023 Capital increase of €7,432 · to €6,992,846.50
- 06-03-2023 Capital increase of €3,346,551.90 · to €6,985,414.50 · 41,163 new shares · in cash
- 15-07-2022 Capital increase of €3,346,551.90 · to €6,985,414.50 · 41,163 new shares · in cash
- 03-06-2020 Capital stated in the deed · €3,577,362.60 · 105,502 shares
Show 2 older capital entries
- 02-09-2019 Incorporation · €61,500
- 02-09-2019 Incorporation · €61,500 · 61,500 shares